TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of Others-Department of Laboratory Medicine
Division of General Internal Medicine
更新時間：2023-09-19
周文堅Chou, Wen-Chien
- Principal Investigator
- Clinical Trial Experience (year) 17 years 9 個月
Publication
16Publications
11
Huang, H. H., Chen, F. Y., Chou, W. C., Hou, H. A., Ko, B. S., Lin, C. T., . . . Chen, R. H. (2019). Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 19. doi:10.1186/s12885-019-5822-y
12
Christen, F., Hoyer, K., Yoshida, K., Hou, H. A., Waldhueter, N., Heuser, M., . . . Damm, F. (2019). Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 133(10), 1140-1151. doi:10.1182/blood-2018-05-852822
13
Liu, J. H., Liao, X. W., Chen, C. H., Yao, M., Li, C. C., Lin, C. T., . . . Ko, B. S. (2019). Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. British Journal of Haematology, 186(1), 72-85. doi:10.1111/bjh.15884
14
Hsu, Y. C., Chen, T. C., Lin, C. C., Yuan, C. T., Hsu, C. L., Hou, H. A., . . . Tien, H. F. (2019). Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials. Blood Advances, 3(15), 2355-2367. doi:10.1182/bloodadvances.2019000391
15
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., . . . Levis, M. J. (2019). Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. New England Journal of Medicine, 381(18), 1728-1740. doi:10.1056/NEJMoa1902688
16
Smith, C. C., Levis, M. J., Perl, A. E., Martinelli, G., Neubauer, A., Berman, E., . . . Bahceci, E. (2019). Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood, 134(Supplement_1), 14-14. doi:10.1182/blood-2019-122620 %J Blood
1
2
